NEW YORK, NY / ACCESSWIRE / April 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BDX Shareholders Click Here: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=6191&wire=1
INO Shareholders Click Here: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=6191&wire=1
EHTH Shareholders Click Here: https://www.zlk.com/pslra-1/ehealth-inc-loss-form?prid=6191&wire=1
* ADDITIONAL INFORMATION BELOW *
Becton Dickinson & Company (BDX)
BDX Lawsuit on behalf of: investors who purchased November 5, 2019 - February 5, 2020
Lead Plaintiff Deadline : April 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=6191&wire=1
According to the filed complaint, during the class period, Becton Dickinson & Company made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements;" (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Inovio Pharmaceuticals, Inc. (INO)
INO Lawsuit on behalf of: investors who purchased February 14, 2020 - March 9, 2020
Lead Plaintiff Deadline : May 12, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=6191&wire=1
According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.
eHealth, Inc. (EHTH)
EHTH Lawsuit on behalf of: investors who purchased March 19, 2018 - April 7, 2020
Lead Plaintiff Deadline : June 8, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ehealth-inc-loss-form?prid=6191&wire=1
The complaint alleges that eHealth, Inc. issued materially false and/or misleading information and/or failed to disclose: (1) its highly aggressive accounting and modeling assumptions; (2) its skyrocketing rate of member churn, resulting from eHealth's pursuit of low quality, lossmaking growth; (3) its reliance on direct response television advertising, which attracts an unprofitable, high churn enrollee; and (4) that as a result of the foregoing, defendants' public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: